Min Cui, PhD, is a Principal at Bay City Capital and has been with the firm since October 2006. Dr. Cui founded /co-founded two biotech companies in the US, as well as a pharmaceutical company in China. Prior to joining Bay City Capital, he was Director of Strategic Investment Planning for Southern Research Institute, an organization that has discovered and developed six anti-cancer drugs approved by the FDA. Dr. Cui served as Chief Scientific Officer and Executive Vice President of Pan Pacific Pharmaceuticals from 1998-2002, and Chief Executive Officer and President of Hucon Biopharmaceuticals from 2003-2005. In these positions, he led efforts to evaluate and acquire several key technologies in the fields of oncology and infectious and inflammatory diseases. Dr. Cui is a member of the board of directors of China Biologic Products (NASDAQ: CBPO) and GenturaDx, and an observer on the board of directors of Ion Torrent Systems. He is a co-founder of CNetwork, a San Francisco-based non-profit organization dedicated to serving Chinese communities in North America.  Dr. Cui received his PhD in Cancer Biology from Stanford University, and his BS in Molecular Biology from Peking University.